Clinical trials located in

Marousi

Marousi city is located in Greece. Currently, 9 clinical trials are being conducted in this city.

Marousi, a vibrant suburb of Athens, Greece, is renowned for its blend of modernity and tradition. This city, birthplace of the ancient sculptor Phidias, is a hub for commerce and culture. It hosted several events during the 2004 Olympics, spotlighting its state-of-the-art Olympic Athletic Center. Marousi is also a green oasis, with lush areas like Syngrou Forest, offering a breath of fresh air amidst urban development. The city’s architectural landscape is a mix of contemporary buildings and historical sites, reflecting its rich heritage and dynamic growth.

  • CT-EU-00034272

    Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Comparing sotorasib and pembrolizumab in treating advanced nonsquamous non-small cell lung cancer

    This trial is testing two first-line therapies in people with advanced lung cancer. Two drugs, Sotorasib and Pembrolizumab, are compared, each combined with a special type of chemotherapy known as a “platinum doublet.” The goal is to determine which combination of these two treatments works most effectively in slowing the growth of the cancer or extending the patient’s life. Patients are selected based on the type and stage of lung cancer. The trial is considered appropriate for people with advanced stage IIIB, IIIC or IV non-squamous non-small cell lung cancer. Additionally, the test is intended for people whose cancer cells show a specific response, including no response to PD-L1, but a positive response to KRAS p. G12C.

    • Sotorasib
    • Pembrolizumab
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing Retifanlimab alone or combined in advanced endometrial cancer

    This research is all about testing a medication called retifanlimab for people who have a late stage of endometrial cancer that’s not improving as desired with a standard drug treatment. This cancer affects the womb lining, and is more severe when it spreads to other body parts. The investigation aims to assess the efficacy of retifanlimab, both as a standalone treatment and in combination with other therapies, to identify the most effective approach to aid individuals grappling with this illness. Monitoring includes tracking the progression of your disease, assessing the duration of your body’s response to the treatment, and observing for any potential side effects or new symptoms that may arise after initiating the new drug.

    • retifanlimab
    • epacadostat
    • INCAGN02385- new potential medication for advanced cancers
    • INCAGN02390- new potential medication for advanced cancer
    • Pemigatinib
  • Comparing methods of medication delivery for melanoma patients: A study on nivolumab and relatlimab treatments

    This clinical trial investigates treatment options for patients with advanced melanoma, comparing subcutaneous and intravenous administration of nivolumab and a fixed-dose combination of nivolumab and relatlimab. The study is designed to determine which method of administration is preferred by patients. Participants will receive either nivolumab alone or in combination with relatlimab, with treatment methods alternating between subcutaneous and intravenous routes. The trial aims to assess not only the safety and effectiveness of these treatments but also gather comprehensive data on patient experiences and preferences regarding the two methods of drug administration. The study will involve regular monitoring and assessments to evaluate treatment outcomes and any potential side effects.

    • rHuPH20
    • Relatlimab
    • Nivolumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Greece:

.